building a


Revance Aesthetics is building the prestige market for aesthetics comprised of expertly created products and services that are available exclusively in select practices who produce exceptional consumer experiences and outcomes.



with product innovation



Our investigational neuromodulator product, DaxibotulinumtoxinA for Injection, is aiming to establish a new, premium, long-lasting neuromodulator category.

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA and is currently under regulatory review.

Filler Technology

The RHA® Collection

The first and only designer hyaluronic acid fillers approved for dynamic wrinkles and folds.

Relational Commerce Platform


The first-of-its-kind Relational Commerce platform built for aesthetic practices. Helping practices move from one-and-done transactions to meaningful seamless relationships through deeper practice insights, greater recurring revenue and higher consumer lifetime value.


Designed to provide leading practices an interactive dimension of learning, RevanceU brings the latest resources in aesthetic science, anatomy and injection technique from global experts directly to you with a variety of peer-to-peer engagements and experiential modules featuring live action videos, 2D and 3D media, and augmented reality (AR).

Press Coverage


“We partner with experienced aesthetic providers who focus on patient outcomes, creating an elevated patient experience as well as innovation in differentiated products, such as the The RHA® Collection ” – Dustin S. Sjuts

Aesthetic News

“The movement component is key…the optimal improvement with filler is when the face looks equally as good at rest as when in motion” – Dr. Ava Shamban MD

New Beauty

“You’ll be hearing a lot about RHA for good reason – this is an advanced HA injectable with natural-looking results.”
-Tracy Teel, BeautyTap Editorial Writer


“Approved by the FDA for the treatment of dynamic facial wrinkles and folds it better mimics natural hyaluronic acid (HA) thanks to less crosslinking.”  -Beth Shapouri


“Revance, the distributor behind…the RHA Collection, is also trying to disentangle the idea of injectables as a commodity and put the focus back on treatments.”
-Emma Sandler, Glossy Sr. Beauty Reporter


Follow Us On Instagram

Let’s set the new standard together

Prestige Portfolio
Differentiated Practice
Elevated Outcomes
RHA® Collection Indications and Important Safety Information

The RHA® collection of resilient hyaluronic acid (HA) fillers includes RHA® 2, RHA® 3 and RHA® 4. RHA® 2 and RHA® 3 are indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds; and RHA® 4 is indicated for injection in the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds; in adults 22 or older.  Read more


Do not use in patients who have severe allergies, marked by a history of anaphylaxis or multiple severe allergies, or in patients with a history of allergies to gram-positive bacterial proteins or local anesthetics of the amide type, such as lidocaine.

Do not use in patients with bleeding disorders.

What are possible side effects?

Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, inject the product slowly and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur.

Product use at specific sites in which an active inflammatory process or infection is present should be deferred until the underlying process has been controlled.


These products should only be used by healthcare professionals who have appropriate training, experience, and knowledge of facial anatomy.

Discuss the potential risks of soft-tissue injections with your patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications.

The safety and effectiveness for the treatment of anatomic regions other than the labeled indications have not been established in controlled U.S. clinical studies.

As with all transcutaneous procedures, dermal filler implantation carries a risk of infection. Standard precautions associated with injectable materials should be followed.

The safety for use in sites in the presence of other implants, during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied.

Use with caution in patients on immunosuppressive therapy.

Patients who are using products that can prolong bleeding (such as thrombolytics, anticoagulants, or inhibitors of platelet aggregation) may experience increased bruising or bleeding at treatment sites.

Patients with a history of herpetic eruptions may experience reactivation of the herpes.

There is a possible risk of inflammation at the implant site if laser treatments or a chemical peel are performed after treatment.

Use as supplied. Modification or use of the product outside the Directions for Use may adversely impact the sterility, safety, homogeneity, or performance of the product.

For single patient use. Do not reuse a syringe between two treatments and/or between two patients. Do not resterilize.

Adverse Events:

The most commonly reported side effects were firmness, redness, tenderness, swelling, lumps/bumps, bruising, discoloration, pain, and itching. Most of these events were mild or moderate and resolved within 14 days.

To report an adverse reaction with any RHA® product, please call Revance at (877) 373-8669.

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA and is currently under regulatory review.